key: cord-0759368-oa42vumr authors: Cao, Albert; Rohaut, Benjamin; Guennec, Loic Le; Saheb, Samir; Marois, Clémence; Altmayer, Victor; Carpentier, Vincent T; Nemlaghi, Safaa; Soulie, Marie; Morlon, Quentin; Berthet-Delteil, Bryan; Bleibtreu, Alexandre; Raux, Mathieu; Weiss, Nicolas; Demeret, Sophie title: Severe COVID-19-related encephalitis can respond to immunotherapy date: 2020-10-16 journal: Brain DOI: 10.1093/brain/awaa337 sha: 2f39e55cdd15be064af2b425975076c9cf525a1d doc_id: 759368 cord_uid: oa42vumr nan patients reinforces the hypothesis of an immune-related mechanism, as evoked by Paterson and colleagues. Neurologists and intensivists should be aware that this life-threatening COVID-19 neurological syndrome has a potentially favourable outcome after immunotherapy, and should not motivate systematic limitation in active patient care. Patients were aged between 37 and 77 years with COVID-19-related encephalitis presenting with altered consciousness, and were treated by PLEX and corticosteroids. They all fulfilled diagnosis criteria for possible immune encephalitis according to Graus et al. (2016) . The clinical presentation and the time-course of the disease are summarized in Table 1 , and complementary explorations findings are summarized in Table 2 (a detailed history is available for each patient in the Supplementary material). Patients had no prior history of neurological disease. They were intubated and mechanically ventilated for COVID-19-related acute respiratory distress syndrome (ARDS). After sedation withdrawal (ranging from Day 12-30 from initiation), they presented severe and persistent consciousness disorder (comatose state or unresponsive wakefulness syndrome), three had oculomotor disturbances (Cases 1, 2 and 3) and one had peripheral symptoms attributed to Guillain-Barré syndrome (Case 3). CSF examinations were unremarkable except in one patient with albuminocytologic dissociation (Case 3), and one with mild pleocytosis (Case 4). Reverse transcription polymerase chain reaction (RT-PCR) assays of the CSF were negative for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), as common viruses for all patients (Supplementary material). Onconeural antibodies were negative in serum and CSF. None of the patients had signs of thrombotic microangiopathy (no haemolysis, normal levels of ADAMTS13 activity and antigen). When performed, somatosensory evoked potentials showed bilateral presence of N20 (Cases 2, 3 and 4). EEGs showed unspecific slow-wave activity. Brain MRIs mostly showed bilateral hyperintense lesions in the deep and periventricular supratentorial white matter, either punctiform and slightly diffuse (Cases 1, 2 and 3) or diffuse and confluent (Cases 4 and 5), associated with lesions in the pons for two patients (Cases 1 and 2) ( Supplementary Fig. 1 ). All patients received immunotherapy combining corticosteroids infusions (1 g/day intravenous methylprednisolone for 5-10 days) and PLEX with albumin (5 to 10 sessions). It is worth noting that neurological impairment remained unchanged in all patients with severe consciousness disorder despite cessation of sedation for 9-33 days. Three patients (Cases 1, 2 and 3) showed dramatic neurological improvement few days after immunotherapy initiation (6, 2, and 7 days, respectively), with consciousness improvement allowing functional communication. Two patients (Cases 4 and 5) showed no signs of consciousness improvement and died after discontinuation of life-sustaining therapies. Although a neuro-invasive potential of SARS-CoV-2 is suspected-as for others coronaviruses-there are surprisingly few reports of COVID-19-associated encephalitis (Hanna Huang et al., 2020; Le Guennec et al., 2020; Moriguchi et al., 2020; Paterson et al., 2020 ). An immune-mediated mechanism has been proposed to explain coronavirusesassociated encephalitis (Weyhern et al., 2020) , and PLEX has shown promising results in a recent case series of COVID-19 mild meningoencephalitis (Dogan et al., 2020) . Reports on patients with positive SARS-CoV-2 RT-PCR assay in the CSF are scarce (Hanna Huang et al., 2020; Moriguchi et al., 2020) and most patients had moderate acute cognitive impairment without pleocytosis (Helms et al., 2020) or mildly elevated CSF cell counts (Bernard-Valnet et al., n.d.) . Likewise, Guillain-Barré and Miller Fisher syndromes, acute necrotizing haemorrhagic encephalopathy, and acute disseminated encephalomyelitis have also been described in COVID-19 patients, suggesting a host-immune response mechanism rather than a direct neuro-invasion of the SARS-Cov-2 (Gutiérrez- Ortiz et al., 2020; Novi et al., 2020; Toscano et al., 2020) . In the Paterson cohort, 10 patients were treated with corticosteroids, and three of these patients also received intravenous immunoglobulin; one made a full recovery, 10 of 12 made a partial recovery, and one patient died (Paterson et al., 2020) . In our cases, the secondary neurological involvement (no prior neurological initial symptoms), associated with the MRI abnormalities and the absence of SARS-CoV-2 in the CSFs point towards a post-infectious antibody or cell-mediated immune mechanism rather than a direct viral neuro-invasion, as suggested by Weyhern et al. (2020) , although no oligoclonal bands and low interleukin-6 were found in the CSFs. The rapid clinical improvement (i.e. 6, 2, and 7 days for Cases 1, 2 and 3, respectively) after immunotherapy was in striking contrast with the protracted persistence of neurological impairment (24, 30, and 31 days, respectively after sedation withdrawal) before treatment initiation. Such a feature supports an inflammatory or immune process. In the instance of critical illness, delayed awakening and cognitive impairment, such as delirium, may result from many factors, such as hypoxic encephalopathy, metabolic disturbances, or side effects of sedation in the case of ICU patients (Mazeraud et al., 2018) . However, ICU-related brain injuries had never been reported to be responsive to immunotherapy. Although we cannot rule out a spontaneous recovery, the rapid improvement after immunotherapy initiation seems to point towards a therapeutic effect of immunotherapy. PLEX and corticosteroid responders (Cases 1, 2 and 3) and non-responders (Cases 4 and 5) shared similar disease courses (severe COVID-19-related ARDS, mechanical ventilation and sedation for several weeks, severe consciousness impairment, which persisted several weeks after sedation withdrawal, unremarkable CSF findings). Differences in treatment response may be related to lesion intensity observed on MRI between the two groups. The responders mainly had small deep white matter lesions while non-responders had more diffuse confluent lesions of the deep white matter. Time of treatment from diagnosis does not seem to be a relevant factor since non-responders received immunotherapy earlier compared to responders (40 and 42 days after COVID-19 symptoms onset for the non-responders, versus 48, 52 and 66 days for the responders). Another cause of treatment failure can also be related to the underlying mechanism: non-responders may have had irreversible necrotic lesions related to vasculopathy and coagulopathy as often seen after COVID-19 infection, especially in the lungs (Helms et al., 2020) . Taken together, our findings support the hypothesis that immunotherapy combining PLEX and corticosteroids can be effective in the treatment of severe COVID-19-related encephalitis. The exact pathophysiological mechanism underlying brain injury has not yet been clarified but a host-immune response to SARS-CoV-2 appears to be a plausible hypothesis. Detailed data are available upon request to the corresponding author. COVID-19 = coronavirus disease 2019; IL-6 = interleukin-6; FLAIR = fluid-attenuated inversion recovery; SWAN = susceptibility weighted magnetic resonance sequences; NP = not performed; RT-PCR = reverse transcription polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. Two patients with acute meningo-encephalitis concomitant to SARS-CoV-2 infection Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: Case series Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy A clinical approach to diagnosis of autoimmune encephalitis Miller Fisher Syndrome and polyneuritis cranialis in COVID-19 A Case of COVID-19 Encephalitis Neurologic Features in Severe SARS-CoV-2 Infection Postinfectious brainstem encephalitis associated with SARS-CoV-2 Orbitofrontal involvement in a neuroCOVID-19 patient Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A Retrospective Case Series Study Social Science Research Network The Sepsis-associated Encephalopathy is Septic A first Case of Meningitis/Encephalitis associated with SARS-Coronavirus-2 Acute disseminated encephalomyelitis after SARS-CoV-2 infection Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features Guillain-Barré Syndrome Associated with SARS-CoV-2 Early evidence of pronounced brain involvement in fatal COVID-19 outcomes This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The Cohort COVID-19 Neurosciences (CoCo Neurosciences), study was sponsored by APHP and funded by the generous support of the Fédération Internationale de l'Automobile (FIA) Foundation and donors of Paris Brain Institute -ICM. The authors report no competing interests.